BIVI News and Press, BioVie Inc. From 04/30/19

LOS ANGELES, April 30, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continu...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...

LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is schedul...

LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a open-label clinic...